Similarly, in human cancers, anti-CD33 therapies like AMV564, a tetravalent bispecific antibody targeting CD33/CD3, have been used to reduce MDSCs and enhance T cell function in patients with myelodysplastic syndromes [232]. Here, CD33 is linked to myelodysplastic syndrome.